Surging ahead in the RSV race, Pfizer buys out a PhII player in $525M M&A pact

John Carroll

Editor & Founder

Right on the heels of back-to-back breakthrough therapy designations for its lead RSV vaccine, Pfizer is wagering up to $525 million on a biotech buyout …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Surging ahead in the RSV race, Pfizer buys out a PhII player in $525M M&A pact

John Carroll

Editor & Founder

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Surg­ing ahead in the RSV race, Pfiz­er buys out a PhII play­er in $525M M&A pact

Editor & Founder

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Surging ahead in the RSV race, Pfizer buys out a PhII player in $525M M&A pact